Regeneron Files BLA For VEGF Trap-Eye In Wet AMD; Second Filing Anticipated This Year
This article was originally published in The Pink Sheet Daily
Executive Summary
If the ophthalmic product wins priority review, Roche could see competition for Lucentis in wet AMD by the fall.
You may also be interested in...
Regeneron/Bayer's Wet AMD Drug Goes Before FDA Panel In June
Regneron and Bayer likely to tout aflibercept's better dosing schedule over Lucentis and may seek further differentiation in wake of Lucentis v. Avastin study.
Regeneron/Bayer's Wet AMD Drug Goes Before FDA Panel In June
Regneron and Bayer likely to tout aflibercept's better dosing schedule over Lucentis and may seek further differentiation in wake of Lucentis v. Avastin study.
Survival Benefit May Position Zaltrap To Compete With Avastin In Second-Line CRC
Full results of the trial will show how Sanofi-Aventis/Regeneron's VEGF Trap performs in patients who have been on Avastin, as well as how the survival advantage stacks up against Avastin.